Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 25, 2016

View Archived Issues

Light-activated quantum dots show promise as phototherapy for multidrug-resistant infections

Oxeia Biopharmaceuticals develops OXE-103 for concussion

Lysyl oxidase identified as a factor in thrombosis risk

FDA approves Botox for the treatment of lower limb spasticity in adults

FDA clears IND application for Agenus' anti-CTLA-4 and anti-GITR antibodies

GSK discontinues development of alitretinoin in U.S.

Phase II results indicate sustained expression with AAT deficiency gene therapy

FDA grants orphan drug designation to TRACON's anti-endoglin antibody

Broad Institute Genomic Services and Takeda partner to expand genomic insight into Ninlaro

Genentech and Xenon Pharmaceuticals patent Nav1.7 channel blockers

Immunocore's IMCgp-100 gets FDA orphan drug designation for uveal melanoma

Incyte discloses KDM1A inhibitors

ST Pharm presents tankyrase-1 inhibitors

Pharmacyclics reports BTK inhibitors

Takeda's H. influenzae type b conjugate vaccine approved in Japan

Bonviva tablet approved in Japan for the treatment of osteoporosis

bioTheranostics to spin out from bioMerieux

Apollo Therapeutics Fund established to advance preclinical drug R&D at U.K. universities

Expanded FDA approvals for Opdivo + Yervoy and single-agent Opdivo in melanoma

Shire's acquisition of Dyax complete

Merck & Co. studies [11C]MK-6884 as PET imaging agent

FDA grants orphan drug designation to mutant KIT inhibitor for mastocytosis

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...